RESUMO
The management of locally advanced or recurrent extremity sarcoma often necessitates multimodal therapy to preserve a limb, of which isolated limb perfusion (ILP) is a key component. However, with standard chemotherapeutic agents used in ILP, the duration of response is limited. Novel agents or treatment combinations are urgently needed to improve outcomes. Previous work in an animal model has demonstrated the efficacy of oncolytic virotherapy when delivered by ILP and, in this study, we report further improvements from combining ILP-delivered oncolytic virotherapy with radiation and surgical resection. In vitro, the combination of radiation with an oncolytic vaccinia virus (GLV-1h68) and melphalan demonstrated increased cytotoxicity in a panel of sarcoma cell lines. The effects were mediated through activation of the intrinsic apoptotic pathway. In vivo, combinations of radiation, oncolytic virotherapy and standard ILP resulted in delayed tumour growth and prolonged survival when compared with standard ILP alone. However, local disease control could only be secured when such treatment was combined with surgical resection, the timing of which was crucial in determining outcome. Combinations of oncolytic virotherapy with surgical resection and radiation have direct clinical relevance in extremity sarcoma and represent an exciting prospect for improving outcomes in this pathology.
Assuntos
Antineoplásicos/administração & dosagem , Quimioterapia do Câncer por Perfusão Regional , Terapia Combinada , Terapia Viral Oncolítica , Radioterapia , Sarcoma/patologia , Animais , Apoptose/efeitos dos fármacos , Caspase 3/metabolismo , Linhagem Celular Tumoral , Modelos Animais de Doenças , Extremidades , Vetores Genéticos/genética , Humanos , Masculino , Melfalan/administração & dosagem , Terapia Viral Oncolítica/métodos , Vírus Oncolíticos/genética , Terapia com Prótons , Radioterapia/métodos , Ratos , Recidiva , Sarcoma/genética , Sarcoma/mortalidade , Sarcoma/terapia , Transdução Genética , Carga Tumoral/efeitos dos fármacos , Carga Tumoral/efeitos da radiaçãoRESUMO
INTRODUCTION: Free flap gene therapy exploits a novel therapeutic window when viral vectors can be delivered into a flap ex vivo. The authors investigated the therapeutic potential of an adenovirally-delivered thymidine kinase/ganciclovir prodrug system expressed following vector delivery into a free flap. METHODS: The authors demonstrated direct in vitro cytotoxicity by treating a panel of malignant cell lines with the thymidine kinase/ganciclovir system and demonstrated significant cell kill proportional to the multiplicity of infection of adenoviral vector expressing thymidine kinase. Bystander cytotoxicity was demonstrated using conditioned media from producer cells (expressing adenovirally-delivered thymidine kinase and treated with ganciclovir) to demonstrate cytotoxicity in naive tumor cells. The authors investigated the effect of adenoviral vector expressing thymidine kinase/ganciclovir therapy in vivo, using models of microscopic and macroscopic residual disease in a rodent superficial inferior epigastric artery flap model. RESULTS: The authors observed retardation of tumor volume growth in both microscopic (p = 0.0004) and macroscopic (p = 0.0005) residual disease models and prolongation of animal survival. Gene expression studies demonstrated that viral genomic material was found predominantly in flap tissues but declined over time. CONCLUSIONS: The authors describe the utility of virally delivered enzyme/prodrug therapy, using a free flap as a vehicle for delivery. They discuss the merits and limitations of this approach and the unique role of therapeutic free flaps among reconstructive techniques available to the plastic surgeon.
Assuntos
Adenoviridae/genética , Ganciclovir/uso terapêutico , Terapia Genética/métodos , Vetores Genéticos , Glioma/terapia , Pró-Fármacos/uso terapêutico , Retalhos Cirúrgicos , Timidina Quinase/administração & dosagem , Ativação Metabólica , Animais , Efeito Espectador , Linhagem Celular Tumoral , Neoplasias Colorretais/patologia , Vírus Defeituosos/genética , Artérias Epigástricas , Ganciclovir/farmacocinética , Regulação Viral da Expressão Gênica , Glioma/patologia , Glioma/cirurgia , Gliossarcoma/patologia , Proteínas de Fluorescência Verde/genética , Humanos , Óperon Lac , Neoplasia Residual , Pró-Fármacos/farmacocinética , Ratos , Simplexvirus/enzimologia , Simplexvirus/genética , Retalhos Cirúrgicos/virologia , Timidina Quinase/metabolismo , Transplante Heterotópico , Proteínas Virais/administração & dosagem , Proteínas Virais/metabolismoRESUMO
Sarcoma of the breast is a rare condition. The biological differences from other primary breast tumours necessitate a corresponding difference in approach to diagnostic and management strategies. The rarity of the condition has made clinicopathological study difficult, with most series limited to less than 50 patients. We review the current literature on the diagnosis and management of breast sarcoma, and highlight areas of likely future development.
Assuntos
Neoplasias da Mama/diagnóstico , Neoplasias da Mama/terapia , Sarcoma/diagnóstico , Sarcoma/terapia , Neoplasias da Mama/mortalidade , Terapia Combinada , Feminino , Humanos , Mamografia , Mastectomia , Sarcoma/mortalidade , Taxa de SobrevidaRESUMO
Acute infection of an aortic graft is a devastating complication. While resection of the infected prosthesis and extra-anatomic bypass is the established treatment, this carries a high mortality. We describe a case of early aortic graft infection with the unusual organism Acinetobacter baumanii, which was eradicated by a combination of surgical drainage and antibiotics, allowing preservation of the graft. The patient remains well 30 months later.